55 related articles for article (PubMed ID: 8866227)
41. The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.
Lobello C; Bikos V; Janikova A; Pospisilova S
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29510549
[TBL] [Abstract][Full Text] [Related]
42. ALK-positive anaplastic large cell lymphoma presenting as intradural spinal mass: first reported case and review of literature.
Novello M; Lauriola L; Della Pepa GM; La Rocca G; Coli A; Visocchi M
Neuropathology; 2013 Aug; 33(4):418-23. PubMed ID: 23082771
[TBL] [Abstract][Full Text] [Related]
43. The role of AP-1 and epigenetics in ALCL.
Schiefer AI; Vesely P; Hassler MR; Egger G; Kenner L
Front Biosci (Schol Ed); 2015 Jun; 7(2):226-35. PubMed ID: 25961698
[TBL] [Abstract][Full Text] [Related]
44. Mass spectrometry-based proteomic studies of human anaplastic large cell lymphoma.
Lim MS; Elenitoba-Johnson KS
Mol Cell Proteomics; 2006 Oct; 5(10):1787-98. PubMed ID: 16785248
[TBL] [Abstract][Full Text] [Related]
45. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools.
Merkel O; Hamacher F; Sifft E; Kenner L; Greil R;
Mol Cancer Ther; 2011 Jul; 10(7):1127-36. PubMed ID: 21712478
[TBL] [Abstract][Full Text] [Related]
46. Nucleophosmin: a versatile molecule associated with hematological malignancies.
Naoe T; Suzuki T; Kiyoi H; Urano T
Cancer Sci; 2006 Oct; 97(10):963-9. PubMed ID: 16984370
[TBL] [Abstract][Full Text] [Related]
47. ALK is a novel dependence receptor: potential implications in development and cancer.
Allouche M
Cell Cycle; 2007 Jul; 6(13):1533-8. PubMed ID: 17611412
[TBL] [Abstract][Full Text] [Related]
48. The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis.
Ducray SP; Natarajan K; Garland GD; Turner SD; Egger G
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366041
[TBL] [Abstract][Full Text] [Related]
49. Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis.
Ye K
Cancer Biol Ther; 2005 Sep; 4(9):918-23. PubMed ID: 16103750
[TBL] [Abstract][Full Text] [Related]
50. Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.
Hoareau-Aveilla C; Meggetto F
Cancers (Basel); 2017 Aug; 9(8):. PubMed ID: 28771164
[TBL] [Abstract][Full Text] [Related]
51. Detection of the NPM-ALK genomic rearrangement of Ki-1 lymphoma and isolation of the involved NPM and ALK introns.
Ladanyi M; Cavalchire G
Diagn Mol Pathol; 1996 Sep; 5(3):154-8. PubMed ID: 8866227
[TBL] [Abstract][Full Text] [Related]
52. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
53. The t(2;5) in human lymphomas.
Kadin ME; Morris SW
Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
[TBL] [Abstract][Full Text] [Related]
54. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma.
Ladanyi M
Cancer Surv; 1997; 30():59-75. PubMed ID: 9547986
[TBL] [Abstract][Full Text] [Related]
55. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
